Why the study?
Does oxprenolol improve cardiac arrhythmias in patients with acute myocardial ischaemia?
Does oxprenolol improve cardiac arrhythmias in patients with acute myocardial ischaemia?
Intravenous oxprenolol effectively suppresses ventricular ectopic beats and supraventricular tachycardia in the setting of acute myocardial ischaemia, though it frequently causes hypotension.
May support cautious IV use in acute ischaemic arrhythmias with BP monitoring; leaves open confirmation in prospective trials.
Oxprenolol, a new beta-receptor blocking drug with intrinsic sympathomimetic activity, was used to treat 63 episodes of cardiac arrhythmia occurring in 43 patients with acute myocardial infarction or myocardial ischaemia. The drug was most effective in abolishing ventricular ectopic beats and supraventricular tachycardia. The best method of administration was by continuous intravenous infusion and the most satisfactory bolus does was 6 mg. The main side effect was hypotension, which occurred in 59% of episodes of arrhythmia that had responded previously to intravenous administration. Oxprenolol was often effective in lignocaine-resistant arrhythmia. The two main advantages of oxprenolol over propranolol are the reduced likelihood of adversely affecting myocardial function and the diminished tendency to produce bronchospasm.
No takes yet. Share an insight, caveat, or question.
Sandler et al. (1971) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: